Falco Holdings
4671.TTSE STANDARDServices
Filed as FALCO HOLDINGS Co., Ltd. (2022-06–2026-07)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥3.3bn | ¥3.4bn | ¥3.0bn | ¥3.4bn | ¥3.8bn | ¥1.9bn |
| Operating income | ¥1.5bn | ¥1.7bn | ¥1.4bn | ¥1.7bn | ¥2.7bn | ¥722m |
| Ordinary income | ¥1.6bn | ¥1.8bn | ¥1.5bn | ¥1.9bn | ¥2.8bn | ¥806m |
| Total assets | ¥24.9bn | ¥24.4bn | ¥24.2bn | ¥26.4bn | ¥24.3bn | ¥24.2bn |
| Net assets / equity | ¥23.0bn | ¥22.4bn | ¥22.9bn | ¥23.2bn | ¥20.1bn | ¥18.0bn |
| EPS (basic) | ¥198.15 | ¥205.29 | ¥171.85 | ¥218.04 | ¥254.07 | ¥96.55 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 74 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 74 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Clinical Testing Business | ¥26.7bn | ¥1.8bn |
| Dispensing Pharmacy Business | ¥15.2bn | ¥674m |
| ICT Business | ¥1.7bn | ¥458m |
| Adjustments & eliminations | — | −¥450m |
| Total | ¥43.6bn | ¥2.9bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.